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Background: Our recent study demonstrated that DNA methylation status in a set of CpGs located in ELOVL2,
C1orf132, TRIM59, KLF14, and FHL2 can accurately predict calendar age in blood. In the present work, we used these
markers to evaluate the effect of allogeneic hematopoietic stem cell transplantation (HSCT) on the age-related
methylation signature of human blood.
Methods: DNA methylation in 32 CpGs was investigated in 16 donor-recipient pairs using pyrosequencing. DNA
was isolated from the whole blood collected from recipients 27–360 days (mean 126) after HSCT and from the
donors shortly before the HSCT.
Results: It was found that in the recipients, the predicted age did not correlate with their calendar age but was
correlated with the calendar age (r = 0.94, p = 4 × 10−8) and predicted age (r = 0.97, p = 5 × 10−10) of a respective
donor. Despite this strong correlation, the predicted age of a recipient was consistently lower than the predicted
age of a donor by 3.7 years (p = 7.8 × 10−4). This shift was caused by hypermethylation of the C1orf132 CpGs, for
C1orf132 CpG_1. Intriguingly, the recipient-donor methylation difference correlated with calendar age of the donor
(r = 0.76, p = 6 × 10−4). This finding could not trivially be explained by shifts of the major cellular factions of blood.
Conclusions: We confirm the single previous report that after HSCT, the age of the donor is the major determinant
of age-specific methylation signature in recipient’s blood. A novel finding is the unique methylation dynamics of
C1orf132 which encodes MIR29B2C implicated in the self-renewing of hematopoietic stem cells. This observation
suggests that C1orf132 could influence graft function after HSCT.
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It has been shown in animal models that elderly individ-
uals exposed to a young systemic environment, for ex-
ample, by surgical connection of the circulatory systems
of young and old animal (heterochronic parabiosis), show
reduced signs of biological aging in the cardiovascular,* Correspondence: rploski@wp.pl
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system [1–3]. Whereas parabiosis is a strictly experimental
system, it has certain similarities with clinical state during
an allogeneic transplantation including bone marrow
transplant or the more often performed peripheral blood
hematopoietic stem cell transplantation (HSCT).
Recently, we described a set of five CpG sites whose
methylation in the whole blood predicts calendar age
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TRIM59 (3q25.33), KLF14 (7q32.3), and FHL2 (2q12.2).
We developed a convenient method based on pyrose-
quencing for robust DNA methylation analysis in 32
CpGs located in these loci including the five best CpG
sites included in the prediction model. Our approach
allowed to predict actual age with mean absolute deviation
(MAD) of 3.9 years and number of correct predictions
(+/−5 years) that ranged depending on age category, from
87 to 50 % [4].
The aim of this study was to evaluate the effect of HSCT
on the age-related methylation signature of human blood
obtained with set of 5 CpG markers of age included in
our age prediction model. In particular, we examined
the effects of donor and recipient age as well as assessed
whether differences existed in post-transplant methylation
dynamics among individual CpG markers.
Methods
Materials
We studied peripheral blood samples from 16 pairs of
donors and recipients. Transplant indications were in line
with the European Group for Blood and Marrow Trans-
plantation (EBMT) guidelines and the searching process
was conducted according to the World Marrow Donor
Association (WMDA) recommendations. Eleven patients
suffered from acute myeloblastic leukemia, two from
myeloproliferative diseases, one from T-cell acute lympho-
blastic leukemia, one from chronic myeloblastic leukemia,
and one from paroxysmal nocturnal hemoglobinuria.
Fourteen pairs were of the same sex; two males received a
transplant from female donors. Samples from the donors
included original samples collected for the purpose of
HLA typing within 6 months before alloHSCT. Samples
from the recipients reconstituted with hematopoietic stem
cells of donor origin were collected at the median time of
91 days (range, 27–360) after alloHSCT. The general char-
acteristics of recipients and donors are shown in Table 1.
Briefly, the median age of recipients at the time of
alloHSCT was 45 (range, 18–59, a detailed list of donors’
and matched recipients’ age is given in Additional file 1:
Table S1). Twelve patients received myeloablative and four
reduced-intensity conditioning. All patients underwent
transplantation from unrelated donors. All patients butTable 1 Characteristics of HSCT recipients and donors
Mean
Recipients (N = 16. 37.5 % of females)
Calendar age 42.0
Donors (N = 16. 50 % of females)
Calendar age 33.9
Period (days) between HSCT and blood sampling in the recipient 125.9
Calendar age difference (recipient-donor) 8.1one were matched with recipients in 10/10 HLA alleles.
All patients received peripheral blood stem cells as a
transplant material. The median age of stem cell donors
was 28 years (range, 20–63). The graft-versus-host disease
prophylaxis included standard doses of cyclosporine (all
patients) and methotrexate (12 patients) or mycophenolate
mofetil (4 patients). Engraftment was achieved by day +20
in all the patients. In all recipients, full chimerism at the
time of blood sample collection for methylation status ana-
lysis was demonstrated by tests performed at respective
clinical centers. In addition, in all DNA samples, the
100 % chimerism was confirmed by analyzing genotypes
of 27 hypervariable STRs using Fusion 6C kit (Promega).
DNA methylation analysis
DNA methylation analysis was performed as described
previously [4]. Briefly, 2 ug of sample DNA was bisulfite
converted using the Qiagen 96-well kit (Qiagen, Hilden,
Germany). PCR reactions were carried out in a total vol-
ume of 25 mL to amplify 5 loci in a total volume of 25 mL
(6p24.2), C1orf132 (1q32.2), TRIM59 (3q25.33), KLF14
(7q32.3), and FHL2 (2q12.2). Negative PCR controls were
included in each PCR amplification. Pyrosequencing was
performed using Pyro Gold reagents on a PyroMark vac-
uum prep workstation and a PyroMark Q24 instrument,
following the manufacturer’s instructions. The generated
pyrograms were automatically analyzed using PyroMark
analysis software (Qiagen, Hilden, Germany). Our approach
allowed to define the methylation status of 32 CpG (7 CpGs
in ELOVL2, 10 CpG in FHL2, 8 CpG in TRIM59, 4 CpG in
KLF14, and 3 CpGs in C1orf132). The positions of these
CpG are given in Table 1 in [4].
Statistical analysis
Correlations were assessed by calculating the Pearson
correlation coefficients (r). We also show r2 values which
indicate the fraction of variance of one variable explained
by the other variable as well as p values. The differences
in the predicted age and in the methylation status in the
donor-recipients pairs were analyzed with paired t test. In
the comparison of methylation status of individual CpG
between donors and recipients, Bonferroni correction was
applied with the correction factor of 32 (i.e., number of all
analyzed CpG). Multivariate analysis was performed withStandard deviation Median Min. Max. Lower quartile Upper quartile
11.5 45 18 59 36 50
13.3 28 20 63 25 40
97.5 91 27 360 41 202
16.8 11 −19 28 −9 22
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the increase in C1orf132 CpG_1 methylation were inde-
pendent variables; donor’s age was the dependent variable).
All calculations were performed with Statistica software
package (StatSoft, Tulsa, OK, USA).
Results
Accuracy of age prediction among donors
Among donors, there was a strong correlation between
the calendar age and the predicted age (r = 0.96, r2 = 0.93,
p = 2 × 10−9, Fig. 1a). Mean absolute deviation (MAD) was
3 years with min. and max. of 0 and 7 and quartile range
from 1.5 to 5 years. The calendar age of 14 out of 16 do-
nors (87.5 %) was predicted with an absolute error ofFig. 1 Correlation between age predicted from methylation and calendar ag
p associated p value. Correlation between the predicted age of HSCT rec
donor (d). Age predicted from methylation in the HSCT recipient-donor p
levels of the studied C1orf132 CpGs in HSCT recipients (R) and donors (D); p v5 years or less. The mean difference between calendar and
predicted age was 1 year, with min. and max. of −7 and
7 years, and quartile range from −1.5 to 4.5 years.
Among HSCT recipients, the predicted age did not
depend on the recipient calendar age but strongly cor-
related with calendar and predicted age of the donor.
Among recipients post HSCT, there was no correlation
between the calendar and the age predicted from the
methylation analysis of the blood DNA (r = 0.134, r2 =
0.018, p = 0.62, Fig. 1b). Of note, analysis of the recipi-
ents’ blood revealed that there was a strong correlation
between the predicted age assessed by the methylation
signature of blood DNA with the calendar age of the
donor (r = 0.94, r2 = 0.89, p = 4 × 10−8, Fig. 1c) as well ase in HSCT donors (a) and recipients (b). r Pearson correlation coefficient,
ipient and calendar age of HSCT donor (c) and predicted age of the
airs; p value was calculated by t test for paired samples (e). Methylation
alues were calculated with paired t test with Bonferroni correction (f)
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the donor’s blood (r = 0.97, r2 = 0.94, p = 5 × 10−10,
Fig. 1d).
The methylation level indicates lower predicted age in
the recipients compared to the predicted age in donors
after HSCT
Despite the very strong correlation between predicted
age of the recipient and the predicted age of the donor,
we noted that in all but one case the age predicted from
the post-HSCT methylation signature of recipient’s blood
was lower than the age predicted from the methylation
signature in the donor of transplanted material (Fig. 1e).
In the case which constituted the exception the age of the
recipient predicted from post HSCT DNA methylation
status was 2 years higher than the age predicted from
DNA methylation status in the respective donor.
The mean predicted age among recipients was 29.2 years
with standard deviation (SD) of 12.3; whereas among the
donors, the respective value was 32.9 years with SD of
13.81. The mean difference between the predicted age
of the donor and the predicted age of the recipient was
3.7 years with SD of 3.52 (p = 0.00078, t test for paired
samples).
The apparent lower predicted age in the recipients
compared to the predicted age in donors seen at the DNA
methylation level (i.e., the difference between the pre-
dicted age of donor and the predicted age of recipient)
did not depend on sex (p = 0.49), the age of recipients
(p = 0.95), the length of period between HSCT and
blood sampling in the recipients group (p = 0.82), or
the difference in the calendar age between the donors
and the recipients (p = 0.14). However, we noted a trend
(p = 0.064) towards a correlation of the size of difference
between predicted age in the recipients and donors, with
donor’s age (r = 0.47) suggesting that this effect may be
more pronounced when HSCT comes from an older
donor (i.e., the older the donor the greater the difference
between the his/her predicted age and the predicted age
of the recipient).
The apparent lower predicted age in the recipients
compared to the predicted age in donors after HSCT is
driven by selective hypermethylation of CpGs within the
C1orf132 locus
We further investigated whether the consistent differ-
ence of ~4 years between the predicted age of recipient
and the predicted age of donor was caused by coherent
effects of all CpG predictors or the direction of DNA
methylation changes was different in particular loci. In
Additional file 1: Table S2, we show the results of com-
parison of recipient vs. donor methylation differences
for all the 5 CpG included in the age prediction model
as well as for the remaining 27 CpGs whose methylationwas assessed in our study. We found that among the
CpG sites included in the model, only CpG_1 at C1orf132
(C1orf132 CpG_1) showed different methylation among
recipients vs. donors (mean difference 8.2 %; SD = 6.9 %
(p = 0.00026; Pcorrected = 0.008).
In order to better estimate the size of this effect, we
developed an age prediction model based solely on CpGs
in C1orf132. The model included C1orf132 CpG_1 and
C1orf132 CpG_3, and it had a reasonable performance
(r = 0.89, r2 = 0.8, and MAD = 6.1 years). Using the
“C1orf132 only” model, the mean predicted age of re-
cipients was 22.4 years and that of donors was 33.8 years,
yielding a difference of 11.3 years (p = 0.000016, paired
t test).
Although we did not detect individual recipient-donor
DNA methylation differences in other loci than C1orf132,
these loci could still have weak effects possibly amounting
to detectable joint influence. In order to test this, we de-
veloped an age prediction model including all loci except
the C1orf132 (r = 0.96, r2 = 0.92, MAD= 4.1 years). Using
this “non-C1orf132 model” the mean predicted age of re-
cipients was 32.1 years and that of donors was 33.1 years,
yielding a difference of 1.1 year which was not statistically
significant (p = 0.28, paired t test).Size of the increase in methylation of C1orf132 CpG_1 in
the recipient vs. donor correlates with calendar age of
the donor
The size of the increase in methylation of C1orf132
CpG_1 in the recipients vs. the donors correlated with the
calendar age of the donors (r = 0.76, r2 = 0.58, p = 0.0006)
but not with sex (r = −0.40, p = 0.12), the recipient’s age
(r = 0.13, p = 0.62), the length of time between HSCT
and blood sampling in the recipient group (r = −0.004,
p = 0.99), or diagnosis (AML vs. other, 9 vs. 6.4 years,
respectively, p > 0.5). The size of the increase in methyla-
tion of C1orf132 CpG_1 in the recipients vs. the donors
nominally correlated also with the recipient-donor calen-
dar age differences (r = −0.51, p = 0.043), but this effect
was no longer observed after adjustment for calendar age
of the donors (p = 0.7). Correlation with the age of the
donors was also found with the recipient vs. donor age
differences calculated using the “C1orf132 only” model
(r = −0.7, r2 = 0.5, p = 0.003).
The increase in the methylation in the recipients vs.
the donors was also apparent for two other C1orf132
CpGs studied; for C1orf132 CpG_2, the difference was
13.4 % (SD = 7.54. p = 0.000003, Pcorrected = 0.0001) and for
C1orf132 CpG_3 it was 13.8 % (SD = 7.8. p = 0.000004,
Pcorrected = 0.00012, Fig. 1f). However, no statistically sig-
nificant correlation was observed between the size of these
effects and the donor’s age or other analyzed variables
(data not shown).
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lation of C1orf132 CpG_1 in the recipient group could
be secondary to the differences in the cellular compos-
ition of the reconstituted hematopoietic system in the
recipients receiving transplant from young vs. older do-
nors. Indeed, when we analyzed donors age vs. white
blood cell (WBC) or counts/percentages of granulocytes/
lymphocytes/monocytes in the recipients, we found that
donor’s age correlated with lymphocyte numbers in the
recipient group (r = 0.78, r2 = 0.61, p = 0.0003). Since
lymphocyte numbers in the recipient also correlated with
the size of the increased C1orf132 CpG_1 methylation in
the recipient vs. donor (r = 0.63, r2 = 0.40, p = 0.009), we
analyzed the effect of lymphocyte numbers and the in-
crease in C1orf132 CpG_1 methylation on donor’s age by
multiple linear regression. We found that lymphocyte
numbers and the difference in C1orf132 CpG_1 methy-
lation between the recipient and donor were independ-
ent predictors of donor’s age (beta = 0.51, p = 0.016 and
beta = 0.44, p = 0.033, respectively).
Discussion
Among human HSCT donors and recipients, we studied
methylation in 5 CpGs recently validated by our group
for age estimation. We found that the methylation signa-
ture of blood post HSCT does not depend on the recipi-
ent age but is strongly correlated with the calendar age
of the donor. However, despite this correlation we ob-
served that the age of HSCT recipient as predicted from
DNA methylation was lower than the age predicted in do-
nors on average by 4 years. Detailed analysis of methyla-
tion status of all studied CpG (N = 32) showed that this
discrepancy was caused by apparently individual effects of
CpGs at the C1orf132 locus.
The age prediction among HSCT donors (who can be
regarded as healthy subjects representative of general
population) independently confirms good performance
of our model [4]. The quality of age prediction achieved
in the present study (MAD = 3 years, 87.5 % correct
predictions) was comparable to that originally reported
(MAD = 3.9, 71.7 % correct predictions) [4], especially
when it was taken into account that majority of the do-
nors were relatively young belonging to age category
20–39 years for which the performance of our model
was better (MAD 3.3, 76.7 % correct predictions) than
for older age groups [4].
The observation that the age of HSCT recipient pre-
dicted by post-transplant DNA methylation analysis per-
formed on DNA isolated from whole blood correlates
with donor’s but not recipient’s age confirms the results
of the recent study by Weidner et al. [5]. Both studies
are consistent in the conclusion that the hematopoietic
niche of the recipient does not noticeably affect age-
associated DNA methylation in blood. It should beemphasized that none of the five CpGs used in our study
overlap with any of the three CpG sites analyzed by
Weidner et al. [5] which argues that the observed effect
is likely to be robust to the exact identity of the set CpG
markers used for age prediction.
Despite the very strong correlation between the age
predicted for blood in the donor and the recipient, we
found that the latter was consistently lower than the
former with an exception observed only in a single pair.
The difference was relatively small (mean 3.7 years) but
it was highly statistically significant. The lower predicted
age in the recipients compared to the predicted age in
donors by ~4 years is directly opposite to the observation
of Weidner et al. [5] who reported that the epigenetic age
predictions were on average 7 years higher than the cal-
endar age of the donor and attributed this finding to
stimulation of hematopoietic stem cells in the donor.
One difference between the two studies is the time
period between HSCT and the recipient’s blood sampling:
in the study of Weidner et al. [5], it was 1 year whereas in
our study it varied from 1 month to 1 year with a mean of
3 months. However, we think it is unlikely that this differ-
ence accounts for the observed discrepancy because we
did not observe any correlation between the length of time
between HSCT and blood sampling in the recipients and
the size of the difference between predicted age in the re-
cipients and the donors. Such a correlation should be ap-
parent if the aging of the transplanted hematopoietic cells
in the donor was indeed fast enough to shift methylation
signature up by 7 years over the time of 12 months as ob-
served by Weidner et al. [5].
Whereas the reasons for the discrepancy between our
results and those of Weidner et al. [5] are not clear, it is
possible that CpG marker selection is important. When
we analyzed CpGs individually we found that the lower
predicted age in the recipients compared to the donors
after HSCT was exclusively caused by hypermethylation
of a single CpG (CpG_1 from the C1orf132 locus) in the
recipient vs. donor whereas the remaining four CpG
from other loci used for age prediction did not show
changes. Furthermore, the remaining two CpGs from the
C1orf132 locus (which were typed but not used for age
prediction) showed even stronger hypermethylation
suggesting that the effect was present among all
C1orf132 CpGs. This together with the absence of a
similar effect among the total of the 29 CpG from the
remaining four loci argues against technical artifacts
and indicates that genuine differences exist in post-
HSCT behavior among loci regarding age-dependent
methylation. Whereas potentially interesting from a
biological perspective, the dissociation of C1orf132
methylation from calendar age in certain circumstances
may decrease the practical usefulness of this locus for age
prediction.
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CpG_1 in the recipients was directly correlated with the
calendar age of the donors—the older the donor, the
higher the methylation. Since C1orf132 methylation de-
creases with calendar age, the increased methylation
could suggest that at this particular CpG HSCT induces
“rejuvenation” which gets stronger with the increasing
age of the donor. However, since HSCT from older do-
nors is less successful than from younger donors [6], it is
unlikely that what we observe is a genuine rejuvenation
with positive clinical consequences. Rather than that we
speculate that C1orf132 hypermethylation in recipients
of HSCT from older donors reflects some problems with
reconstitution of hematopoietic system to the state in
which it was present in the donor. This may be linked
with delayed or failed restoration of certain types of cells
or certain states of their chromatin. It is also possible
that senescence-associated methylation changes contrib-
ute to the observed effect.
The C1orf132 has recently been shown to encode a
long no-coding RNA (lncRNA) which at its 3′ end in-
cludes microRNA MIR29B2C [7]. Whereas the C1orf132
function remains unclear, it is intriguing that in mice,
the miR29 family (miR29ab1 and miR29b2c) has been
implicated in the self-renewing ability of HSCs as well as
determination of organ and body size [8]. Our results
suggest that the C1orf132/MIR29B2C locus could also
be important for graft function after HSCT and thus
should be studied further as a potential graft function/
prognostic marker.
Due to relatively small number of studied subjects our
study had limitations. Whereas in our data the correla-
tions between donor’s age on one side and C1orf132
methylation and lymphocyte numbers on the other side
appeared independent from each other definite conclu-
sions are difficult. Furthermore, we cannot exclude that
C1orf132 methylation is a marker of a subset of cells
whose development primarily depends on the donor’s age
and which were not specifically analyzed by us. Studies of
these issues are warranted in the future. Finally, our study
may not have had sufficient power to detect a significant
correlation between the differences in predicted age of do-
nors vs. recipients and the time length from HSCT to
blood sample collection.
In conclusion, using an independent set of CpG
markers, we confirm that after HSCT the age of the
donor is the major determinant of age-specific methyla-
tion signature in recipient’s blood whereas the age of
recipient does not exert a detectable effect. As a novel
finding, we show that in HSCT setting, methylation at
C1orf132 has unique dynamics and depends on the age
of the donor. The methylation at C1orf132 locus should
be interesting for further studies of HSCT prognostic
markers.Conclusions
After HSCT, the age of the donor is the major determinant
of age-specific methylation signature in recipient’s blood.
After HSCT methylation of C1orf132, which en-
codes MIR29B2C implicated in the self-renewing of
hematopoietic stem cells, it has a unique dynamics
suggesting that this locus could influence graft function.
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